

Reports of advisory bodies

Expert committees and study groups

Expert advisory panels and committees and their membership

Report by the Secretariat¹

ESTABLISHMENT OR DISESTABLISHMENT OF EXPERT ADVISORY PANELS

1. The panel on sexually transmitted infections, including those due to human immunodeficiency virus, was disestablished in November 2016.

MEMBERSHIP OF THE EXPERT ADVISORY PANELS

2. Membership of the 44 expert advisory panels totalled 568 in December 2016, compared with 602 in December 2015. In terms of regional distribution, 12% come from the African Region, 24% from the Region of the Americas, 11% from South-East Asia Region, 29% from the European Region, 9% from the Eastern Mediterranean Region and 15% from the Western Pacific Region. Of the total of all members of all panels, 32% are women.

3. The annexed list of all panels includes a breakdown of members by panel, region and sex, as of December 2016. Further details (lists of experts by region and country) are available on request.

MEETINGS OF EXPERT COMMITTEES

4. The following committees met in 2016:

Expert Committee on Specifications for Pharmaceutical Preparations (Fifty-first meeting)
Geneva, 17–21 October 2016 (14 members: nine men, five women)

Joint FAO/WHO Expert Committee on Food Additives (Eighty-second meeting)
Geneva, 7–16 June 2016 (eight members: five men, three women)

¹ This report is submitted to the Executive Board in compliance with regulation 4.23 of the Regulations for Expert Advisory Panels and Committees.

Joint FAO/WHO Expert Committee on Food Additives (Eighty-third meeting)
Rome, 8–17 November 2016 (seven members: five men, two women)

Expert Committee on Drug Dependence (Thirty-eighth meeting)
Geneva, 14–18 November 2016 (14 members: five men, nine women)

Expert Committee on Biological Standardization (Sixty-seventh meeting)
Geneva, 17–21 October 2016 (14 members: eight men, six women).

5. Invitations to take part in these meetings were extended to 57 panel members from 27 different countries, drawn from four expert advisory panels. All members were able to attend.

ANNEX

MEMBERSHIP OF EXPERT ADVISORY PANELS BY PANEL AND REGION¹

| Expert Advisory Panels | Africa | | The Americas | | South-East Asia | | Europe | | Eastern Mediterranean | | Western Pacific | | Total | | |
|---|----------|----------|--------------|----------|-----------------|----------|----------|----------|-----------------------|----------|-----------------|----------|-----------|----------|-----|
| | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | % |
| Acute bacterial diseases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ageing and health | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 4 | 2 | 50 |
| Biological standardization | 0 | 0 | 5 | 1 | 1 | 1 | 3 | 0 | 0 | 0 | 3 | 1 | 12 | 3 | 25 |
| Blood transfusion medicine | 7 | 3 | 3 | 2 | 5 | 3 | 5 | 1 | 6 | 3 | 6 | 4 | 32 | 16 | 50 |
| Clinical practice guidelines and clinical research methods and ethics | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 3 | 1 | 33 |
| Clinical surgical procedures | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 4 | 0 | 0 |
| Drug dependence (dependence liability evaluation) | 4 | 4 | 7 | 3 | 5 | 3 | 5 | 1 | 2 | 1 | 4 | 1 | 27 | 13 | 48 |
| Drug dependence and alcohol problems | 1 | 0 | 4 | 2 | 3 | 1 | 5 | 1 | 2 | 0 | 7 | 1 | 22 | 5 | 23 |
| Drug evaluation | 7 | 1 | 10 | 3 | 6 | 6 | 13 | 3 | 7 | 2 | 6 | 2 | 49 | 17 | 35 |
| Drug policies and management | 3 | 1 | 3 | 2 | 2 | 2 | 3 | 2 | 0 | 0 | 2 | 1 | 13 | 8 | 62 |
| Food safety | 1 | 0 | 15 | 5 | 1 | 1 | 8 | 2 | 1 | 0 | 6 | 1 | 32 | 9 | 28 |
| Health laboratory services | 0 | 0 | 3 | 1 | 0 | 0 | 4 | 1 | 4 | 2 | 1 | 1 | 12 | 5 | 42 |
| Health promotion | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 100 |

¹ Number of panel members as at December 2016 where *N* equals the total number of panel members, *W* equals the number of women members and % represents the percentage of women panel members by panel and region.

| Expert Advisory Panels | Africa | | The Americas | | South-East Asia | | Europe | | Eastern Mediterranean | | Western Pacific | | Total | | |
|---|--------|---|--------------|----|-----------------|---|--------|----|-----------------------|---|-----------------|---|-----------|----|----|
| | N | W | N | W | N | W | N | W | N | W | N | W | N | W | % |
| Health science and technology policy | 0 | 0 | 5 | 3 | 1 | 0 | 2 | 1 | 1 | 0 | 1 | 1 | 10 | 5 | 50 |
| Human cell, tissue and organ transplantation | 1 | 0 | 3 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 10 | 3 | 30 |
| Human genetics | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Immunology | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Injury and violence prevention and control | 2 | 1 | 4 | 2 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 11 | 3 | 27 |
| International pharmacopoeia and pharmaceutical preparations | 13 | 2 | 15 | 11 | 3 | 1 | 34 | 14 | 5 | 1 | 11 | 2 | 81 | 31 | 38 |
| Leprosy | 2 | 1 | 2 | 1 | 2 | 0 | 4 | 0 | 1 | 0 | 2 | 0 | 13 | 2 | 15 |
| Malaria | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 5 | 0 | 0 |
| Management of noncommunicable diseases | 5 | 3 | 2 | 1 | 3 | 1 | 6 | 1 | 1 | 1 | 2 | 1 | 19 | 8 | 42 |
| Medicine safety | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 1 | 0 | 6 | 2 | 33 |
| Mental health | 1 | 0 | 3 | 0 | 3 | 2 | 2 | 0 | 0 | 0 | 2 | 0 | 11 | 2 | 18 |
| Neurosciences | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 50 |
| Nursing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Nutrition | 0 | 0 | 18 | 5 | 3 | 1 | 11 | 7 | 5 | 2 | 8 | 1 | 45 | 16 | 36 |
| Oral health | 0 | 0 | 0 | 0 | 3 | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 8 | 2 | 25 |
| Parasitic diseases – filarial infections | 3 | 1 | 4 | 0 | 4 | 2 | 1 | 0 | 1 | 0 | 1 | 0 | 14 | 3 | 21 |
| Parasitic diseases – general parasitology | 2 | 0 | 3 | 2 | 1 | 1 | 7 | 1 | 1 | 0 | 1 | 0 | 15 | 4 | 27 |
| Parasitic diseases – leishmaniasis | 0 | 0 | 4 | 3 | 4 | 1 | 6 | 1 | 1 | 0 | 0 | 0 | 15 | 5 | 33 |
| Parasitic diseases – schistosomiasis | 3 | 1 | 6 | 0 | 0 | 0 | 6 | 2 | 2 | 0 | 4 | 0 | 21 | 3 | 14 |
| Parasitic diseases – trypanosomiasis | 4 | 0 | 3 | 2 | 0 | 0 | 6 | 1 | 0 | 0 | 0 | 0 | 13 | 3 | 23 |

| Expert Advisory Panels | Africa | | The Americas | | South-East Asia | | Europe | | Eastern Mediterranean | | Western Pacific | | Total | | | |
|---|-----------|----------|--------------|----------|-----------------|----------|------------|----------|-----------------------|----------|-----------------|----------|-------------|----------|----|----|
| | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | <i>N</i> | <i>W</i> | % | |
| Prevention of blindness | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Prevention of deafness and hearing impairment | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 50 |
| Rabies | 1 | 0 | 3 | 1 | 2 | 0 | 2 | 0 | 1 | 0 | 1 | 1 | 10 | 2 | 20 | |
| Radiation | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 50 | |
| Rehabilitation | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | |
| Traditional and complementary medicine | 3 | 0 | 3 | 1 | 1 | 0 | 3 | 0 | 1 | 0 | 7 | 0 | 18 | 1 | 6 | |
| Tuberculosis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Vector biology and control | 0 | 0 | 0 | 0 | 2 | 1 | 9 | 2 | 1 | 0 | 2 | 1 | 14 | 4 | 29 | |
| Virus diseases | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | |
| Virus diseases (antivirals and interferon) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Zoonoses | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 0 | 0 | 5 | 2 | 40 | |
| Total | 67 | 18 (27%) | 139 | 54 (39%) | 60 | 30 (50%) | 167 | 46 (28%) | 52 | 15 (29%) | 83 | 21 (25%) | 568* | 184 | 32 | |

*Note: This is the total number of experts. Members with more than one nationality are listed in all relevant panels, however they are counted only once in this total.